North American Travelan sales up 98% in the first half of FY20

Key Highlights:

• Strong continued growth of Travelan sales reported in all markets
• North American Travelan sales up by 98% YoY in the first half of FY20
• Immuron achieved 55% YoY growth for the first half of FY20, with worldwide sales reaching AU $1.68M
• US Travelan sales exhibited 39% YoY growth for first half FY20, reaching AU $514K
• Total Australian sales experienced 33% YoY growth for first half FY20, reaching AU $954K

MELBOURNE, Australia, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced the sales results of its commercially available and over-the-counter gastrointestinal and digestive health supplement Travelan for the first half of fiscal year 2020 ending on December 31, 2019.

Immuron experienced robust gross sales growth in the US, Canada and Australia throughout the first half of FY20, with global sales reaching AU $1.68M* during the 6-month period.

North America sales of Travelan were up 98% YoY for the first half of FY20, spurred on by the launch of Travelan in Canadian pharmacies in June 2019 and also by robust growth in online Amazon sales within the US.  Passport Health, the USA’s largest travel medicine provider, also contributed to the strong result, with Travelan sales rising by 27% within the Passport Health network of clinics. A series of podcasts on the “Not old, better” network assisted in raising consumer awareness of Travelan in the US.

In Australia, Immuron sales reached AU $954K* for the first half FY20, displaying a 33% YoY growth rate. Travelan strengthened its presence in Australian pharmacies with in-store promotional material and TV advertising with Chemist Warehouse. Immuron’s participation in Medical Practitioner conferences also contributed to increased awareness of Travelan within the medical community.

“The sales momentum for Travelan which was already evident during the first quarter of fiscal year 2020 has continued unabated throughout the first half of fiscal year 2020 as consumer awareness of Travelan continues to grow,” said Dr. Gary S. Jacob, CEO of Immuron Ltd. “As we step through the second half of this fiscal year we will continue to focus on increasing consumer awareness of the brand, particularly in North American markets, as we look to expand the market for this important health care product. At the same time, we are seeking FDA registration for Travelan as a drug to prevent travelers’ diarrhea which we believe will provide a further boost to our sales potential moving forward.”